Amyloid Oligomer Conformation in a Group of Natively Folded Proteins by Yoshiike, Yuji et al.
Amyloid Oligomer Conformation in a Group of Natively
Folded Proteins
Yuji Yoshiike
1, Ryoichi Minai
2, Yo Matsuo
2, Yun-Ru Chen
3, Tetsuya Kimura
1, Akihiko Takashima
1*
1Laboratory for Alzheimer’s Disease, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan, 2Computational Proteomics Team, RIKEN Genomics Sciences Center,
Tsurumi-ku, Yokohama, Japan, 3The Genomics Research Center, Academia Sinica, Taipei, Taiwan
Abstract
Recent in vitro and in vivo studies suggest that destabilized proteins with defective folding induce aggregation and toxicity
in protein-misfolding diseases. One such unstable protein state is called amyloid oligomer, a precursor of fully aggregated
forms of amyloid. Detection of various amyloid oligomers with A11, an anti-amyloid oligomer conformation-specific
antibody, revealed that the amyloid oligomer represents a generic conformation and suggested that toxic b-aggregation
processes possess a common mechanism. By using A11 antibody as a probe in combination with mass spectrometric
analysis, we identified GroEL in bacterial lysates as a protein that may potentially have an amyloid oligomer conformation.
Surprisingly, A11 reacted not only with purified GroEL but also with several purified heat shock proteins, including human
Hsp27, 40, 70, 90; yeast Hsp104; and bovine Hsc70. The native folds of A11-reactive proteins in purified samples were
characterized by their anti-b-aggregation activity in terms of both functionality and in contrast to the b-aggregation
promoting activity of misfolded pathogenic amyloid oligomers. The conformation-dependent binding of A11 with natively
folded Hsp27 was supported by the concurrent loss of A11 reactivity and anti-b-aggregation activity of heat-treated Hsp27
samples. Moreover, we observed consistent anti-b-aggregation activity not only by chaperones containing an amyloid
oligomer conformation but also by several A11-immunoreactive non-chaperone proteins. From these results, we suggest
that the amyloid oligomer conformation is present in a group of natively folded proteins. The inhibitory effects of A11
antibody on both GroEL/ES-assisted luciferase refolding and Hsp70-mediated decelerated nucleation of Ab aggregation
suggested that the A11-binding sites on these chaperones might be functionally important. Finally, we employed a
computational approach to uncover possible A11-binding sites on these targets. Since the b-sheet edge was a common
structural motif having the most similar physicochemical properties in the A11-reactive proteins we analyzed, we propose
that the b-sheet edge in some natively folded amyloid oligomers is designed positively to prevent b aggregation.
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Introduction
Protein misfolding diseases are characterized by the formation
of amyloid, which occurs through misfolding promoted by the
conversion of a protein from its native to non-native state. Under
the appropriate conditions, any proteins can form generic amyloid
[1]. The ability of an oligomeric entity in amyloid to seed the
polymerization of other proteins indicates that amyloid may
disrupt cellular functions by interfering with the folding of other
proteins [2–5, Kayed et al., Society for Neuroscience Abstracts
2005;35:893.6]. Therefore, it is important to understand the
molecular mechanism(s) underlying the seeding function of
amyloid oligomers, whose pathogenic significance in protein
misfolding diseases have been well supported. Because amyloid
oligomers innately tend to aggregate, high-resolution elucidation
of their structures through conventional physical techniques has
been challenging. Novel insight on the structure of amyloid
oligomers was made possible by the development of an anti-
amyloid oligomer conformation-dependent antibody, A11 [2].
The fact that various amyloid oligomers are A11 immunopositive
suggests that amyloid oligomers share a common structure and
implies that various protein-misfolding diseases may have a
common pathogenic mechanism [2]. In the present study, we
identified proteins that contain the amyloid oligomer conforma-
tion by using the A11 antibody as a probe. One group of A11-
reactive proteins commonly displayed anti-b-aggregation activity
as opposed to the expected b-aggregation promoting activity of
misfolded amyloid oligomers.
Results
Amyloid oligomer conformation in chaperones
A11 is an antibody that specifically detects the conformation of
amyloid oligomers regardless of their amino acid sequence [2]. To
determine whether proteins that contain the amyloid oligomer
conformation exist in bacteria, we examined the A11 immunore-
activity of Escherichia coli cell lysates. We chose to examine bacterial
proteins because extensive structural information about these
proteins already exists in the protein data bank (PDB). We
subjected E. coli DH5a cell lysates to PAGE analysis. To reduce
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SDS nor reducing agents to solubilize the lysates although the
disruption of conformation was predicted to some extent during
SDS-PAGE. One gel was Western blotted with A11 to identify the
molecular weights of A11-immunoreactive proteins (Figure 1A),
and another gel was stained with coomassie brilliant blue (CBB).
The bands in the CBB-stained gel corresponding to the A11-
immunoreactive bands on the immunoblot were analyzed by
tandem mass spectrometry (MS-MS). We identified one of these
A11-immunoreactive bands to contain GroEL, a bacterial
chaperonin [6]. Unlike other proteomics studies that have used
sequence-dependent antibodies, in our study, the proteins detected
in the cell lysates through this simple approach remain
unconfirmed candidates of A11-reactive proteins. Indeed, the
conformational specificity of A11 for each protein (purified and
native forms) needs to be analyzed, since the cell lysis procedure
might have affected protein conformation to unknown degrees.
To confirm the A11 immunoreactivity of GroEL, we performed
Western analysis on purified GroEL and observed that A11
strongly immunostained monomeric GroEL (Figure 1B). Although
the sample buffer used in this PAGE analysis lacked SDS and
reducing agents, the running buffer did contain SDS. In true
native PAGE, which is performed without SDS, A11 mostly
immunostained a high molecular weight band representing a
GroEL oligomer complex, which is the expected functionally
active form of GroEL in bacterial cytosol (Figure 1C). A11
antibody also strongly immunostained purified GroEL on dot blots
(Figure 1D). This enabled us to exclude the possibility that the
PAGE processing misfolded GroEL molecules that potentially
could react with A11 and lead to false A11 positives. A11 antibody
also immunostained purified recombinant human chaperones,
including heat shock protein (Hsp) 27, 40, 70, 90; yeast Hsp104;
and bovine heat shock cognate (Hsc) 70, albeit with varying
intensity (Figure 1D). As expected, A11 antibody immunostained
b-amyloid (Ab) oligomer prepared from Ab(1–40) but not
monomeric Ab. These results suggest that certain chaperone
structures share a common amyloid oligomer conformation.
Among the A11-reactive candidates, we were interested in
identifying chaperones that normally display anti-aggregation
activity as opposed to proteins, such as misfolded pathogenic
amyloid oligomers, that induce b-aggregation of other proteins [2–
5, Kayed et al., Society for Neuroscience Abstracts 2005;35:893.6].
Proteins containing the amyloid oligomer conformation
affect Ab aggregation in opposite ways
To confirm the seeding property of pathogenic Ab oligomer, we
assessed the b-aggregation kinetics of Ab40 in the presence of
preformed Ab oligomer using a thioflavin T (ThT) fluorescence
assay [7] (Figure 2A), and found that Ab oligomer induced Ab
aggregation in a dose-dependent manner. To determine whether
the chaperones we assessed with A11 antibody were functionally
active and thus natively folded or misfolded like pathogenic amyloid
oligomers, we examined the effects of Hsp27, Hsp70, and Hsp90 on
Ab-aggregation kinetics using the ThT assay [7] (Figure 2B–D). Ab,
a type of amyloid protein observed in Alzheimer’s disease (AD), has
been pathologically linked to these three chaperones [8]. As with
other published studies [9,10], we found that all three chaperones—
Hsp27, Hsp70, and Hsp90—suppressed the b aggregation of Ab in
a dose-dependent manner to varying degrees. We did not observe
fibrillar amyloid structures in Ab samples incubated with each of
these chaperones under an electron microscope (data not shown).
To verify this chaperone activity [6], we examined whether the anti-
b-aggregation properties of Hsp was energy dependent (Figure 2E,
F). Adding ATP to samples containing Hsp70 or Hsp70/Hsp40 at
concentrations that alone do not show anti-b-aggregation activity
caused Hsp70 and Hsp70/Hsp40 to significantly suppress Ab
aggregation. Most of the purified recombinant chaperones used
here, including Hsp70 and Hsp40, have tested positive for their
ATPase activity. The energy-dependent anti-b-aggregation activity
of these chaperone samples indicates that A11-immunoreactive
chaperones are indeed functional; thus, a significant number of
chaperone molecules in these purified samples are natively folded
[4,11]. In other words, the native structures of these chaperones
possess the amyloid oligomer conformation. Therefore, there are at
least two classes of A11-reactive proteins that contain the amyloid
oligomer conformation: pathogenic amyloid oligomers that pro-
mote b aggregation and chaperones that suppress b aggregation.
Figure 1. Amyloid oligomer conformation in chaperones. (A) E.
coli competent cells (strain DH5a; TOYOBO, Japan) were freeze-thawed
three times by freezing the cells on ice at 2180uC then thawing them at
37uC. The lysates were then mixed with sample buffer lacking SDS and
reducing agents and then subjected to PAGE analysis. One gel was
immunoblotted with A11 antibody. A11-immunoreactive bands (A–G)
were excised from the CBB-stained gel, treated with trypsin, and
analyzed by tandem-mass spectrometry. A candidate A11-reactive
protein from band B was GroEL. The difference in staining patterns
between the A11 immunoblot and CBB-stained gel indicates A11
antibody-binding selectivity. Note also that the proteins in cell lysates
reacted with the A11 antibody are not necessarily all natively folded.
Purified GroEL (23 mM) was mixed with sample buffer lacking both
reducing agents and SDS, and then run on (B) a gel in a regular SDS-
containing buffer or (C) a gel in a buffer lacking SDS (native PAGE). Gels
were blotted onto a membrane that was subsequently probed with A11
under the same conditions. Note that the mobility of the molecular
weight standard is different in (B) and (C). (D) The following solutions
(3 mL each) were dot blotted onto a nitrocellulose membrane: 20 mM
Ab40 monomer, 20 mMA b40 oligomer, H2O, purified 23 mM GroEL,
37 mM Hsp27, 20 mM Hsp40, 14 mM Hsp70, 12 mM Hsp90, 10 mM
Hsp104, and 10 mM Hsc70. GroEL, Hsp27, Hsp40, Hsp90, and Hsc70
were purchased from Stressgen (Canada). Hsp70 was from Sigma (USA).
Hsp104 was from ATGen (South Korea). Each protein solution was
blotted onto a single membrane that was probed with A11 under the
same conditions. The individual dot blots were arranged into a single
column.
doi:10.1371/journal.pone.0003235.g001
Native Amyloid Oligomers
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anti-b-aggregation activity of Hsp27
Next, we examined how heat treatment alters the amyloid
oligomer conformation of Hsp27 and the Hsp27-mediated
suppression of Ab aggregation (Figure 3). We assessed Hsp27
because of its strong A11 immunoreactivity on both dot blot and
native-PAGE/Western blot analyses, and because of its patholog-
ical association with Ab [8]. We heated Hsp27 dissolved in buffer
to 80uC for 15 and 30 min and then subjected the sample to
native-PAGE followed by Western blotting with A11 antibody.
Heat treatment abolished A11 immunoreactivity of Hsp27
(Figure 3A), even though the peptide backbone of Hsp27 was
intact (SDS-PAGE of heat-treated samples, Figure 3B). ThT assay
of samples containing Ab and heat-treated Hsp27, however,
showed that Hsp27-mediated suppression of Ab aggregation
disappeared concurrently with the reduction of amyloid oligomer
Figure 2. Contrasting effects of Ab oligomer and chaperones on Ab aggregation. (A)A b40 (final concentration: 5 mM) dissolved in aCSF
was mixed with 0, 0.5, 5, or 50 nM Ab40 oligomer (i.e., ‘‘seed’’) in H2O. Results from a sample containing only 50 nM Ab40 oligomer is also shown. ThT
fluorescence intensity indicates the level of Ab aggregation. (B)A b40 (final concentration: 10 mM) dissolved in H2O was mixed with 0, 10, 100, or
1000 nM Hsp27 in buffer (1.08 mM Tris-HCl [pH 7.5], 541 mM NaCl, 54.1 mM EDTA, and 54.1 mM DTT). (C)A b40 (final concentration: 10 mM) dissolved
in H2O was mixed with 0, 10, 100, or 1000 nM Hsp70 in buffer (2.7 mM KCl, 1.5 mM KH2PO4, 137 mM NaCl, and 8.1 mM Na2HPO4). (D)A b40 (final
concentration: 5 mM) dissolved in H2O was mixed with 0, 5, 50, or 500 nM Hsp90 in buffer (3.9 mM Tris-HCl [pH 7.5], 7.8 mM NaCl, and 78.2 mM DTT).
(E) Anti-b-aggregation activity of Hsp40 and Hsp70. Ab40 (5 mM) dissolved in aCSF was mixed with either 10 nM Hsp70 in buffer A (15.1 mM KCl,
8.4 mMK H 2PO4, 767 mM NaCl, and 45.3 mMN a 2HPO4) or a mixture of 10 nM Hsp70 in Buffer A and 10 nM Hsp40 in Buffer B (10.8 mM KCl, 6.0 mM
KH2PO4, 548 mM NaCl, and 32.4 mMN a 2HPO4) in the presence or absence of 500 mM Mg-ATP. (F) Bar graph showing ThT fluorescence intensity of Ab
samples with or without chaperones after 17 h of incubation. Statistical significance was calculated by using a Student’s t-test. *p=0.035;
**p=0.00046. Data are presented as means+/2SEM.
doi:10.1371/journal.pone.0003235.g002
Native Amyloid Oligomers
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heat-denaturing experiments simply suggested that the conforma-
tion-specific binding of A11, and thus the amyloid oligomer
conformation—not non-specific interactions—was consistently
observed as natively folded Hsp27 prevented b aggregation.
These results certainly did not demonstrate that the A11-reactive
domain within Hsp27 is responsible for suppressing Ab aggrega-
tion. Both the structure and functional mechanisms of Hsp27 are
unknown. Since the spherical and oligomeric forms of Hsp27 are
active states [12], Hsp27 could co-oligomerize with Ab while
suppressing amyloidogenesis. Heat-treated Hsp27 may have also
formed amyloid that complexed with Ab. Taken together, these
data identify the amyloid conformation as the generic structural
feature of natively folded chaperones directly correlating with the
anti-b-aggregation activity of chaperones.
A11 immunoreactivity and anti-b-aggregation activity in
non-chaperone proteins
Anti-b-aggregation activity is not unique to chaperones. Thus, if
chaperones with anti-b-aggregation activity contain the amyloid
oligomer conformation, we assumed that other proteins known to
suppress Ab aggregation might also contain the amyloid oligomer
conformation. One such protein is transthyretin (TTR), which has
been shown to sequester Ab and prevent amyloid formation
[13,14]. We confirmed the suppressive effect of TTR on Ab
aggregation in our model system (Figure 4A). Another protein with
anti-Ab-aggregation properties is a2-macroglobulin (a2MG). Al-
though the genetic association between a2MG and AD remains
controversial [15], the anti-b-aggregation activity of a2MG against
Ab has been reported to occur in vitro [16,17], as we also observed
(Figure 4B). As expected, A11 antibody immunostained dot blots of
TTR and a2MG (Figure 4C), indicating that both proteins possess
the amyloid oligomer conformation. Although TTR is a protein
that forms amyloid in pathogenic conditions, its A11 immunore-
activity has never been reported [18]. If a significant number of
TTR molecules somehow misfold and bind to A11 in solution, they
are more likely to induce or cross-seed Ab aggregation, as other
misfolded pathogenic amyloid oligomers [2–5, Kayed et al., Society
for Neuroscience Abstracts 2005;35:893.6]. In our experiment, this did
not occur. Instead TTR suppressed Ab aggregation (Figure 4A)
[13,14], indicating that the amyloid oligomer conformation within
TTR is not misfolded but is natively folded.
Analysis of the crystal structures of the TTR and a2MG
receptor-binding domains reveal that both contain a b sandwich
with a jelly-roll topology [19,20]. The crystal structures of
diphtheria toxin (DT) and exotoxin A (ETA) also have a
homologous jelly-roll-like topology [21,22]. As expected, A11
antibody also immunostained both DT and ETA (Figure 4C).
Surprisingly, these amyloid oligomer conformation-containing
toxins also suppressed Ab aggregation in vitro in a dose-dependent
manner, even though they have no known physiological
relationship to Ab (Figure 4D, E). These results suggest that A11
immunoreactivity is not only found in chaperones but is also found
among certain non-chaperone proteins possessing anti-b-aggrega-
tion activity.
Comparative analyses require control experiments. Thus in the
present study, we tested whether A11-immunonegative proteins
fail to inhibit b aggregation. Different chain lengths of D-poly
glutamic acids (pdE) and L-poly glutamic acids (plE) did not
exhibit A11 immunoreactivity or inhibit b aggregation, instead
they promoted b aggregation (Figure 4F–H). These results support
the conformational specificity of A11 antibody binding. Indeed,
plE mostly exists as a random coil at neutral pH [23], the same pH
we used in our control experiment. These results also suggest that
A11 reactivity, and thus amyloid oligomer conformation, is not the
only functional determinant of b-aggregation-promoting activity.
Because we did not test the anti-b-aggregation activity of all
purified and folded A11-non-reactive proteins, we could not
exclude the possibility that an A11-non-reactive protein possessing
anti-b-aggregation activity exists. For the same reason, our current
results cannot exclude the possible existence of A11-reactive folded
proteins that do not possess anti-b-aggregation activity. Therefore,
Figure 3. Effects of heat treatment on amyloid oligomer
conformation in Hsp27 and the anti-b-aggregation activity of
Hsp27. (A) Western blot of Hsp27 probed with A11 anti-amyloid
oligomer conformation-dependent antibody. Hsp27 samples were heat
treated at 80uC for 15 or 30 min. Heat-treated and untreated Hsp27
samples (10 mM) were mixed with sample buffer lacking SDS and
reducing reagents, subjected to native PAGE using 4–20% gels, and
separated proteins were immunoblotted with A11 antibody. Note that
A11-immunoreactive Hsp27 bands migrated to a high molecular-weight
level in native PAGE, because Hsp27 exists as large oligomers having
chaperone-like activity [8,12]. (B) Heat-treated and untreated Hsp27
samples (10 mM) were mixed with sample buffer containing SDS and b-
mercaptoethanol, and then subjected to SDS-PAGE using 4–20% gels.
Gels were stained with coomassie brilliant blue (CBB). (C)A b-
aggregation kinetics of samples containing heat-treated Hsp27. One
buffer sample and three Hsp27 samples were diluted 100 times with
H2O. Ab40 (final concentration: 5 mM) dissolved in aCSF was mixed with
buffer (54 mM Tris-HCl [pH 7.5], 27 mM NaCl, 2.7 mM EDTA, and 2.7 mM
DTT); untreated 50 nM Hsp27; 15-min heat-treated Hsp27; or 30-min
heat-treated Hsp27. All samples were incubated in the presence of
10 mM ThT; triplicate measurements were taken every 30 min at
excitation and emission wavelengths of 440 nm and 486 nm [7],
respectively. Data are presented as means+/2SEM.
doi:10.1371/journal.pone.0003235.g003
Native Amyloid Oligomers
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prerequisite for anti-b-aggregation activity.
A11 affects GroE-assisted luciferase refolding and Hsp70-
decelerated Ab nucleation
To determine whether the A11-binding site plays a functional
role in protein folding, we first investigated the effects of A11
antibody on GroEL/ES (GroE)-assisted firefly luciferase refolding.
Luciferase samples were heated at 45uC for 5 min. After cooling
the samples at room temperature for 5 min and adding luciferin
substrate, GroEL/ES and ATP facilitated luciferase refolding,
which was evident by the increased luminescence in the samples
(Figure 5A). Luminescence was not observed in heat-treated
samples co-incubated with GroEL/ES and ATP in the presence of
A11. This suggests that A11 prevented GroEL/ES-assisted
refolding of heat-denatured luciferase. Surprisingly, A11 itself
assisted luciferase refolding to a similar extent as GroEL/ES.
Antibody-assisted refolding of proteins, including luciferase, has
been reported previously in cases in which an antibody specific to
a given protein facilitates antigen folding [24,25]. Therefore, we
surmised that the A11-assisted refolding of luciferase we observed
might involve A11 binding to luciferase, which also possesses a b
motif [26]. Thus, we tested the A11 immunoreactivity of purified
luciferase by dot blot (Figure 5B). The luciferase sample exhibited
A11 immunoreactivity that was weaker than that of the positive
GroEL control blotted on the same membrane. These results
provide a possible explanation for the assisted refolding of
luciferase by A11: Like other antibodies having chaperone-like
activity, A11 may induce luciferase refolding through specific
interactions. If this is the case, then the diminished refolding of
luciferase in samples containing both chaperonin and A11 is more
likely due to the interaction of A11 with chaperonin rather than
the interaction of A11 with luciferase.
Next, we examined how A11 affects Hsp70-mediated suppres-
sion of Ab aggregation by assessing Ab aggregation kinetics
(Figure 5C). The presence of Hsp70 decelerated the nucleation of
Ab aggregation. This effect was suppressed by A11, even though
elongation was not substantially affected. This result indicates that
the A11-binding site on Hsp70 may play a role in inhibiting
nucleation but not elongation during Ab aggregation. Interesting-
ly, A11 alone failed to substantially affect Ab aggregation at the
concentration used. It will be interesting to examine in further
detail whether A11 assists or prevents the oligomerization of Ab
and other amyloidogenic proteins. The present results indicate
that A11-binding sites on chaperones may be functionally
important.
Deduction of A11-epitope and amyloid oligomer
conformation through structural similarity search
Our analysis of A11 immunoreactivity and anti-b-aggregation
activity of purified proteins led us to identify at least ten A11-
reactive folded proteins with reported crystal structures. These
included associated protein fragments and corresponding homo-
logues from different species. Information about A11-immunore-
active proteins and their atomic structures may help us deduce the
conformation shared by amyloid oligomers. To determine the A11
epitope and thus amyloid oligomer conformation, we searched
each of the ten crystal structures for areas sharing the most surface
physicochemical properties (see Methods). For the similarity
search, we placed two main restrictions according to the known
properties of amyloid oligomer conformations. First, the search
was limited to only structures having a b strand, which is a
generally accepted basic component of amyloid. Second, the
search was limited to only areas that are less influenced by amino
acid side chains, because A11 immunoreactivity is conformation
dependent not amino-acid-sequence dependent [2]. Areas show-
ing the most similarity are shown in red for each of the ten crystal
structures (Figure 6 and Figure S1). All areas were located at the
side edge of the b-sheet conformation, which comprises most of
larger b-structural motifs such as the b-sandwich motif. Some of
the potential A11-binding areas were located at or near the
suggested substrate-binding domain of chaperones (e.g., GroEL,
Hsp70, Hsc70, Hsp40) [27–30], while other potential A11-binding
areas were not (e.g., ClpB [Hsp104] and Hsp90) [31–33]. The Ab-
binding site of TTR, previously identified through site-directed
mutagenesis as well as through molecular modeling [13,34],
partially matched the area proposed here as the A11 epitope.
Interestingly, the displacement of this particular terminal b strand
by a conformational change promotes fibril formation of TTR
itself [35]. These observations support the hypothesis that the b-
sheet edge, a common feature of the ten crystal structures we
assessed, plays a key role in A11-reactive proteins. Indeed, the
negative design of the b-sheet edge supposedly helps natural b-
sheet proteins to avoid b aggregation [36]. Here, we propose that
b-sheet edge in natively folded amyloid oligomers not only protects
proteins from undergoing b aggregation but also prevents
interacting molecules from undergoing b aggregation. Thus, in
some cases this can be considered to be a positive design. How the
amyloid oligomer conformation influences protein conformation
still needs to be determined in the future. This can be achieved by
investigating the detailed molecular interactions between chaper-
one/chaperone-like proteins and the A11 antibody and between
these proteins and amyloidogenic proteins.
Discussion
By using the A11 antibody, an antibody known to detect the
conformation of amyloid oligomers [2], we unexpectedly observed
the amyloid oligomer conformation in a group of proteins whose
folds were functionally characterized as native on the basis of their
anti-b-aggregation activity. This contrasts with the misfolded
pathogenic amyloid oligomers that promote b aggregation [2–5,
Kayed et al., Society for Neuroscience Abstracts 2005;35:893.6]. Because
we propose a novel corollary to the original claim that A11
recognizes a common structure shared by oligomeric intermedi-
ates formed by a diverse range of amyloidogenic proteins [2], our
results were carefully examined.
Figure 4. Dose-dependent suppression of Ab aggregation by A11-immunoreactive non-chaperone proteins. (A)A b40 (final
concentration: 5 mM) dissolved in aCSF was mixed with 0, 50, 500, or 5000 nM TTR in 10 mM Tris-HCl (pH 7.4) with 0.9% NaCl. ThT fluorescence
indicates the level of Ab aggregation. (B)A b40 (final concentration: 5 mM) dissolved in H2O was mixed with 0, 5, 50, or 500 nM a2MG in buffer
(1.45 mM Tris-HCl [pH 8.0], 9.4 mM glycine, and 5.8 mM trehalose). (C) Dot blot of 100 mM TTR, 13.8 mM a2MG, 17.2 mM DT, and 15.2 mM ETA (3 ml
each) probed with A11 antibody [2]. (D) and (E)A b40 (final concentration: 5 mM) dissolved in aCSF was mixed with buffer alone; 5, 50, or 500 nM DT;
or ETA. For (D), the buffer contained 10 mM Tris-HCl (pH 7.4) and 1 mM EDTA. For (E), the buffer contained 10 mM sodium phosphate (pH 7.5) and
150 mM NaCl. (F) Dot blot of 100 mM pdE (approx. MW: 50 kDa); 10 mM plE (approx. MW: 1000 Da); and 50 mMA b40 oligomer (3 ml each) probed
with A11, secondary antibody alone without primary antibody, and 4G8 antibody (which reacts to amino acid residues 17–24 of human Ab). (G) and
(H)A b40 (final concentration: 5 mM) dissolved in PBS was mixed with buffer alone; 0.05, 0.5, 5 mM pdE; or plE. Data are presented as means+/2SEM.
doi:10.1371/journal.pone.0003235.g004
Native Amyloid Oligomers
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non-specific effect caused, for example, by a small fraction of
partially misfolded A11 antibody? We considered that this was
unlikely because heat-denatured Hsp27 did not bind A11
Figure 6. Sites with physicochemical properties of greatest
similarity among ten A11-reactive proteins. The crystal structures
of ten A11-reactive proteins were aligned to identify the areas where
the physicochemical properties of solvent-exposed atoms show the
highest similarity (red). (A) GroEL [1aon]. (B) a2MG [1ayo]. (C) Hsp40
[1c3g]. (D) DnaK (Hsp70) [1dkz]. (E) TTR (prealbumin) [1dvq]. (F) ETA
[1ikq]. (G) DT [1mdt]. (H) ClpB (Hsp104) [1qvr]. (I) Hsc70 [1yuw]. (J)
Hsp90 [2cg9]. The PDB codes of the structures used in the structural
similarity search are shown in square brackets.
doi:10.1371/journal.pone.0003235.g006
Figure 5. A11-mediated inhibition of GroE-assisted luciferase
refolding and Hsp70-mediated decelerated Ab nucleation. (A)
In a sample of GroE (final concentrations: 1.25 mM GroEL and 2.1 mM
GroES) and luciferase (final concentration: 100 nM), about 30% of
luciferase activity was recorded relative to the activity of luciferase
samples without heat-treatment, indicating that GroE-assisted partial
refolding of heat-denatured luciferase had occurred. Luciferase activity
was not observed when heat-treated luciferase was co-incubated with
both GroE and A11 (final concentration: 0.1 mg/mL). A11 antibody
assisted the refolding of luciferase (n=15 for GroE and n=6 for GroE/
A11 and A11 alone, respectively). Data are presented as means+/2SEM.
(B) Three microliters of 250 nM GroEL, 2.5 mM luciferase, and H2O were
blotted onto a nitrocellulose membrane. The membrane was incubated
either with the A11 antibody in 5% skim milk or with just skim milk. (C)
Ab40 (final concentration: 5 mM) dissolved in aCSF was mixed with or
without Hsp70 (final concentration: 75 nM) and A11 (final concentra-
tion: 300 nM). All samples were incubated in the presence of 5 mM ThT.
Triplicate measurements were taken every 30 min. Average fluores-
cence values are plotted. Error bars were omitted from the graph for
clarity.
doi:10.1371/journal.pone.0003235.g005
Native Amyloid Oligomers
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(Figure 4). Moreover, none of the identified A11-immunoreactive
proteins bound secondary antibody in samples lacking A11 (data
not shown).
Could the anti-b-aggregation activity of the identified proteins
be induced by colloidal or crowding effects? We considered this to
be unlikely because Hsp70/40 exhibited energy-dependent anti-b-
aggregation activity (Figure 2E). Heat-treated Hsp27 (Figure 3C)
and polyglutamate (Figure 4G,H) did not show the anti-b-
aggregation activity. In addition, crowded GroE/A11 mixtures
did not facilitate luciferase refolding more than less crowded GroE
or A11 solutions (Figure 5A). Along similar lines, crowded Hsp70/
A11 mixtures did not enhance anti-b-aggregation activity more
than less crowded Hsp70 solutions (Figure 5C).
Could A11 be recognizing traces of misfolded amyloidogenic
intermediates of these proteins? We considered that this was
unlikely because if the contaminating molecules of such misfolded
amyloid intermediates were substantially present in the sample,
then we would expect the A11-reactive proteins, especially non-
chaperone proteins like toxins, not to suppress b aggregation
(Figure 4D, E). Rather, we would expect them to promote b
aggregation as Ab oligomers did (Figure 2A), because misfolded
amyloid oligomers characteristically promote oligomerization and
fibrillization of other proteins, a suggested pathogenic mechanism
underlying protein misfolding diseases [2–5, Kayed et al., Society for
Neuroscience Abstracts 2005;35:893.6]. A functional property that was
commonly observed in the group of A11-reactive proteins was
anti-b-aggregation activity, which differentiated these proteins
from misfolded pathogenic amyloid oligomers, which promote b-
aggregation. Together with the conformation-specific nature of
A11 reactivity, this phenomenon led us to conclude that a
significant number of molecules in the purified samples were
neither misfolded nor unfolded, but were most likely natively
folded.
Does the notion of a ‘‘common structure’’ mean anything if it so
diverse it encompasses the folded and misfolded proteins? Under
the right conditions, any protein can form amyloid [1]. The
formation of amyloid structures by poly amino acids supports the
premise that amyloid formation occurs independent of specific
side-chain contacts or amino acid sequences [37]. Although plE
forms amyloid at pH 4.1, it exists mostly as a random coil at
physiological pH [23]. Indeed, plE dissolved in a neutral pH buffer
showed neither A11 immunoreactivity nor anti-b-aggregation
activity, which is consistent with the conformational specificity of
A11 binding (Figure 4F–H). The difference in the staining patterns
in immunoblots probed with A11 and in CBB-stained gels of
bacterial cell lysate samples (Figure 1A) indicates that A11 does not
bind just any protein. Not all A11-reactive proteins in the bands
were necessarily natively folded or retained their in vivo
conformation, since lysing the cells can significantly affect the
conformation of some proteins. We believe that A11 specificity
does exist, as demonstrated in the original study [2]. It is most
important to note, however, that the specificity of A11 is
completely different from that of other antibodies that recognize
specific amino acid sequences in that A11 reactivity depends on
the three-dimensional conformation of a protein since A11
specifically binds oligomeric intermediates but not unfolded
monomers or fibers of amyloidogenic proteins [2]. Thus, A11
reactivity is independent of an antigen’s amino acid sequence,
because A11 specifically binds oligomeric intermediates formed by
a diverse range of amyloidogenic proteins. The conformational-
dependent binding specificity of A11 also implies that the amyloid
oligomer represents a generic conformation [2]. On the basis of
this particular generic property of the A11 antibody, we believe
that A11 antibody is also capable of binding a group of natively
folded proteins, as we observed in the present study.
What is the functional significanceof having an amyloid oligomer
conformation within natively folded proteins? Function-blocking
experiments clarifiedthe functional importanceof A11-binding sites
on chaperones (Figure 5).To further tackle this issue structurally, we
took a computational approach. A functional property shared by
pathogenicamyloidoligomersandchaperonesis that both affectthe
conformation of unfolded proteins. This property might depend on
the structural plasticity that is shared by amyloid and the substrate-
binding domain of chaperonin, called the apical domain [38–41].
The structural plasticity of amyloid is partially based on its
polymorphism, the ability of one polypeptide to form aggregates
of different structures [39]. Indeed, the polymorphic nature of
amyloid setsitapartfromotherglobularfoldedproteinswith unique
structures. Thus, it is unlikely that the amyloid oligomer
conformation is represented by a unique structure.
On the other hand, amyloid also exhibits isomorphism, the
ability of different polypeptides to display similar morphologies
[2,39]. Taking advantage of this property, we searched for areas
containing similar physicochemical properties on the surfaces of
the crystal structures of A11-reactive folded proteins (Figure 6 and
Figure S1). Our analysis results were consistent with the proposed
structures of amyloid protofilaments or precursors [42–46].
Although the non-native amyloid precursor of b2-microglobulin
is highly native-like, its edge strands contain perturbations that
normally protect b-sandwich proteins from self-association [43–
46]. Structurally, the edges of a completely regular b-sandwich
motif are inherently b-aggregation prone [36]. Coincidentally, our
structural similarity search revealed that the b-sheet edge of
GroEL was located in the apical domain. A pioneering study on
GroEL suggested that chaperonins act by stabilizing non-native
intermediates against off-pathway misfolding and aggregation
[27]. Because b-sheet structures are primarily formed through
main-chain hydrogen bonds [4,6], the induction of b-strand
formation in a substrate through the b-sheet edge in the apical
domain of GroEL may normally function to prevent non-specific
side-chain contacts and thus non-specific aggregation, but in
certain cases promote b aggregation as reported previously
[47,48]. We consider this idea to be speculative but consistent
with the formation of b-strands by non-native substrates in a
complex structure with Hsp40, and consistent with Hsp40-
dependent amyloid assembly in cells [30,49].
Finally, we would like to mention evolutionary aspects of
‘native’ amyloid oligomers. The presence of the amyloid oligomer
conformation within a natively folded protein indicates that the
folding observed in this type of conformation is based on amino
acid sequence, which is encoded in that particular protein’s gene
according to Anfinsen’s hypothesis [11]. On the other hand, the
unprecedented diversity of proteins containing amyloid oligomer
conformations also indicates that the folding in these conforma-
tions may be caused by something else, especially in pathogenic
conditions [1,2,4]. In evolution, aggregative properties of some
proteins may have pressured the selection of anti-aggregation
properties in some genes as a preventive measure. On the basis of
the generic anti-aggregation characteristics of certain A11-reactive
folded proteins, such as the chaperone family, we hypothesize that
(1) the amyloid oligomer conformation has evolved over time as a
means to prevent non-specific protein aggregations, and that (2)
based on the structural commonality, amyloidogenic proteins may
sporadically deviate from this system of preventing protein
aggregation in some conditions such as aging in the extended
life span of humanity today that has not been caught up by
evolution.
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Immunoblot (Western blot and dot blot)
Separated proteins by SDS-PAGE were transferred onto
nitrocellulose membranes by using a wet system at 4uC.
Alternatively, 3 mL of sample solution was dot-blotted onto
membranes. After being blocked with milk, the blotted membrane
was probed with anti-amyloid oligomer antibody A11 (1:1000;
Biosource, USA) [2] or 4G8 (1:1000; Signet, USA). A11 and 4G8
antibody immunoreactivity were detected with HRP-conjugated
anti-rabbit IgG (1:2500) or anti-mouse IgG (1:5000), respectively,
followed by ECL. A replicated membrane probed with the
secondary antibody alone did not display signals. Each panel
displaying an immunoblot was from a single membrane and thus a
single experiment. For presentation purposes, the squares
containing each dot blot were arranged in a single column or
row for figures.
Ab oligomer preparation
Ab oligomer was prepared as described previously [2]. Briefly,
lyophilized Ab40 peptide (Peptide Institute, Japan) was dissolved
in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) (Wako, Japan) on ice
and aliquoted to be frozen until use. Ab was spin-vacuumed just
prior to the experiment; dissolved in HFIP solution (final
concentration: 10% (v/v) HFIP); and kept at room temperature
under constant stirring. After 2 days, the tube was transferred to
and maintained at 4uC.
Thioflavin T (ThT) assay
Lyophilized Ab40 peptide was first dissolved in HFIP on ice.
Most of the HFIP was vacuum evaporated before Ab was
dissolved in H2O; PBS; or artificial cerebrospinal fluid (aCSF:
124 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 2 mM MgSO4,
1.25 mM NaH2PO4, 26 mM NaHCO3, and 10 mM glucose).
Solubilized Ab40 (5 mM) was mixed with a protein dissolved in a
respective buffer. Note that different buffer conditions resulted in
different aggregation kinetics of Ab. ThT (10 mM unless
otherwise noted) was added to each solution to assess the
formation of b-sheet structures. Samples were incubated at 37uC
in 96-well plates; triplicate measurements were taken every
30 min with an ARVO multilabel spectrofluorometer (PerkinEl-
mer, USA). Plates were shaken for 10 sec prior to every
measurement. Excitation and emission wavelengths were 440
and 486 nm, respectively [7]. In each experiment, triplicate wells
containing protein sample at each concentration without Ab were
made. Results from the measurement of these wells were not
included in the figures because the values were significantly
smaller than those of wells with Ab.
Luciferase refolding assay
Twenty microliters of 250 nM luciferase (Sigma) in 100 mM
Tris-HCl (pH 7.4) and 5 mL of 20 mM DTT in H2O were mixed
in each well of a 96-well plate. For heat treatment, plates were
sealed and placed in an incubator maintained at 45uC. After
5 min, the plates were taken out and kept at room temperature for
5 min. Next, 2.5 mL of 40 mM DTT (Nacalai Tesque), samples
representing four different conditions, and 2.5 mL of 80 mM Mg-
ATP (Sigma) in H2O were added to each well. The four samples
were as follows: (1) 15 mLo fH 2O; (2) 5 mLo fH 2O, 5 mLo f
12.5 mM GroEL, and 5 mLo f2 1mM GroES; (3) 5 mL of 1 mg/
mL A11, 5 mL of 12.5 mM GroEL, and 5 mLo f2 1mM GroES;
and (4) 5 mL of 1 mg/mL A11, and 10 mLo fH 2O. The plate was
incubated at 30uC for 1 h. As soon as 5 mL of 2 mM luciferin
(Nacalai Tesque) dissolved in 100 mM Tris-HCl (pH 7.4) was
added to each well, the luminescence was measured with an
ARVO multilabel spectrofluorometer (PerkinElmer). The average
luminescence value from H2O-incubated wells was subtracted
from the luminescence value measured from other wells. The
percentage of luminescence recorded in each well was calculated,
taking as 100% the average value measured from wells that were
not heat treated. The percentages determined for each condition
were averaged and defined as percent (%) luciferase activity. GroE
represents the combination of both GroEL and GroES.
Structural similarity search
Ten PDB files of A11-immunoreactive proteins were retrieved.
In the preliminary search, 214 potential sites on the surfaces of
ten structures were detected among the areas where the main b-
sheet chain was exposed to the surface (Table 1). Atoms in these
sites were first classified into six physicochemical types using the
PATTY algorithm [50]. Structural alignment was carried out by
aligning the spatial coordinates of atoms at every two sites and
identifying pairs of atoms of the same physicochemical type. We
then calculated similarity scores for these aligned structures.
Twenty-three sites with relatively high similarity scores were
determined using a clustering algorithm. For each structure, we
selected sites having the highest similarity score. We then
constructed a figure by performing multiple structure alignments
on the ten sites having the highest similarity scores. Surface
atoms were determined by calculating accessible surface areas
(.0A ˚ 2) at 1.4 A ˚ of probe atoms. The atoms were clustered
using the single-linkage clustering algorithm with a cutoff value
of 4 A ˚. Clusters formed by less than four atoms were removed.
Surface atoms that existed within 4 A ˚ from atoms of the
remaining clusters were included. Each cluster was defined as a
single site.
Similarity score. Each atom located on a structure’s surface
was given a feature vector. The feature vector describes the local
physicochemical environment of a surface atom. Atoms were first
classified into six physicochemical types using the PATTY
algorithm [50]: cation (AT1), anion (AT2), hydrogen-bond donor
(AT3), hydrogen-bond acceptor (AT4), hydrophobic (AT5), and
none of these (AT6). An atom that was both a hydrogen-bond
donor and an acceptor (‘polar’ atom, according to the PATTY
algorithm) was treated as 0.5 donor and 0.5 acceptor. The feature
vectors were defined for each atom according to this atom-type
Table 1. Potential surface sites on ten A11-reactive proteins
in which the main b-sheet chain is exposed to the surface.
PDB code Number of sites
1aon 114
1ayo 8
1c3g 6
1dkz 5
1dvd 7
1ikq 7
1mdt 15
1qvr 13
1yuw 13
2cg9 26
Total 214
doi:10.1371/journal.pone.0003235.t001
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Ci~
X
j h
j
AT1,h
j
AT2,...,h
j
AT6
  
,
in which the summation was over all the solvent-accessible atoms
(including atom i) of the protein, h
j
ATx~a 1{dij
 
dc
  
if dij/dc#1,
and atom j is of type ATx; otherwise, h
j
ATx~0. If atom j is both a
donor and an acceptor and x=3 or 4, a=0.5; otherwise, a=1. dij
is the distance (in A ˚) between atom i and atom j. The parameter
values dc=3.2 were used. The similarity between each pair of
atoms from the two regions was assessed by sij=TC(i, j), where
atoms i and j were from regions a and b, respectively; and TC(i,j)i s
the Tanimoto coefficient:
TC i,j ðÞ ~
P 6
n~1
CinCjn
P 6
n~1
Cin ðÞ
2z
P 6
n~1
Cjn
   2{
P 6
n~1
CinCjn
:
Finally, a similarity score S was defined for the two regions a and
b: S=Ssij/min{Na,Nb}, where sij is defined as above; Na and Nb are
the numbers of atoms of regions a and b, respectively; and the
summation was over all atom pairs in the alignment except for
those pairs of different atom types. Possible S values ranged from 0
to 1, where 1 represents the maximum similarity.
Supporting Information
Figure S1 Sites having the most similar physicochemical
properties in the molecular structures of ten A11-reactive proteins.
Because the aligned site in 1aon was hidden from view at the
viewing angle we used for the other structures, only 1aon is shown
from a different angle from other molecules. (A) GroEL [1aon]. (B)
a2MG [1ayo]. (C) Hsp40 [1c3g]. (D) DnaK (Hsp70) [1dkz]. (E)
TTR (prealbumin) [1dvq]. (F) ETA [1ikq]. (G) DT [1mdt]. (H)
ClpB (Hsp104) [1qvr]. (I) Hsc70 [1yuw]. (J) Hsp90 [2cg9].
Found at: doi:10.1371/journal.pone.0003235.s001 (8.92 MB TIF)
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